Present Role of Surgery for Brain Metastases

Carapella, Carmine Maria; Oppido, Piero Andrea

doi:10.1016/j.wneu.2018.09.202

Cited by 5 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Effective local treatments for brain metastases include surgery, SRS and WBRT ( 20 , 21 ). In our study, patients who received local therapy for brain metastases received no survival benefit.…”

Section: Discussionmentioning

confidence: 99%

Clinical features and prognostic factors in 190 cancer patients with brain metastases

Zhou¹,

Wu²,

Sun³

2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: Brain metastases significantly reduce the survival of cancer patients. However, detailed researches on the clinical manifestations and prognoses of patients with brain metastases are lacking. The aim of this study was to investigate the clinical features and prognostic factors of cancer patients with brain metastases.Methods: A retrospective study was conducted on patients with brain metastases who were treated in our hospital between January 2014 and January 2019. Comparison of overall survival (OS) was performed by the Kaplan-Meier method. Multivariate Cox regression models was used to identify prognostic factors for OS. Results: A total of 190 patients with complete data and Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2 were enrolled. Patients with brain metastases from different primary sites had significantly different survival time (P=0.001). Patients who had a longer survival time included female patients (47.4%) (34 vs. 19 months, P=0.002), those with age <65 years (63.7%) (29 vs. 18 months, P=0.002), with ECOG 0 or 1 (44.2%) (32 vs. 21 months, P=0.005), with ≤3 brain lesions (61.1%) (29 vs. 20 months, P=0.041), and with small molecular targeted therapy (48.4%) (21 vs. 18 months, P=0.006). Furthermore, multivariate analysis revealed that female, age <65 years, ≤3 brain lesions, small molecular targeted therapy were independent favorable prognostic factors of OS.Conclusions: Female, younger patients with ≤3 brain metastases predicted a better survival. To improve the poor outcomes of these patients, it is necessary to find clinically significant genetic abnormalities and administer the small molecular targeted therapy early in the course of treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical features and prognostic factors in 190 cancer patients with brain metastases

Zhou¹,

Wu²,

Sun³

2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

show abstract

“…Cerebral metastases are the other tumor group we evaluated in our study; they are the most common cranial tumors in adults. 9 10 Cerebral metastases can be seen in approximately 20% of patients with malignancy. 10 The increase in the incidence of cancer and the prolongation of the life span of patients with cancer increase the number of patients with cerebral metastases.…”

Section: Introductionmentioning

confidence: 99%

“…This is followed by breast cancer, skin tumors, and gastrointestinal system tumors. 9 10 In this research, cases who underwent stereotactic biopsy were analyzed retrospectively according to distribution of pathological diagnoses over the years, importance of immunohistochemical markers in diagnosis, and demographic characteristics.…”

Section: Introductionmentioning

confidence: 99%

Retrospective Evaluation of Cases Undergoing Stereotaxic Brain Biopsy

Yolcu,

Akar,

Aker

et al. 2023

Asian J Neurosurg

View full text Add to dashboard Cite

Objective: The aim of this study is to evaluate the demographic, radiological and histopathological findings, tumoral biomarkers, and survival rates of patients who underwent a stereotactic brain biopsy and those diagnosed with glioblastoma, metastasis, and lymphoma, and the changes in the diagnosis distribution over the years. Materials and Methods: The patients who underwent stereotactic biopsy in our clinic between 2012 and 2020 were evaluated retrospectively. Metastasis, glioblastoma, and lymphoma cases were evaluated as three main groups and the others were excluded. P53 gene expression, isocitrate dehydrogenase (IDH) mutation, and Ki-67 values in glioblastoma cases and Bcl-2, Bcl-6 proteins, and Ki-67 values in lymphomas and their relationship with survival were evaluated. Results: High p53 expression was observed in 27.5% cases diagnosed with glioblastoma. IDH mutation was negative in all glioblastoma cases. Presence of Bcl-2 and Bcl-6 proteins was not associated with survival in lymphomas. Survival rate was significantly higher in cases diagnosed with lymphoma (26.9%) compared to those diagnosed with glioblastoma. A statistically significant increase was determined in patients diagnosed with lymphoma considering the distribution of diseases and incidence and in the distribution of other diagnoses over the years (p < 0.05). Conclusion: As per the distribution of the disease in recent times, it has been observed that there is an increase in lymphoma cases. Histopathology and biomarkers have great importance in the diagnosis and treatment of cerebral lesions. We think that our findings will be supported by studies in which larger patient population and detailed biomarkers will be studied.

show abstract